To determine the impact of adjunctive Buchang Naoxintong Capsule ( , NXT ) on dual antiplatelet therapy in patients with cytochrome P@ @C@ * @ ( CYP@C@ * @ ) polymorphism undergoing percutaneous coronary intervention ( PCI ) .